Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 7.
doi: 10.1111/jgs.70143. Online ahead of print.

SGLT2 Inhibitors in Older Adults With Cardiovascular Disease: A Systematic Review and Meta-Analysis

Kota Minami  1 , Rika Terashima  2   3 , Lina Freeman  4 , Yuji Yamada  5 , Amanda R Vest  6 , Yuichiro Yano  7   8 , Toshio Naito  7 , Satoshi Miyashita  6   7   9
Affiliations

SGLT2 Inhibitors in Older Adults With Cardiovascular Disease: A Systematic Review and Meta-Analysis

Kota Minami et al. J Am Geriatr Soc. .

Abstract

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, developed for type 2 diabetes mellitus (T2DM), have demonstrated cardiorenal benefits in conditions including cardiovascular (CV) disease. However, few meta-analyses have synthesized outcomes in older adults with CV disease.

Methods: A systematic review and meta-analysis of randomized controlled trials published from January 2015 to January 2025 was conducted using MEDLINE (PubMed), Embase (Ovid), and CENTRAL. We included studies that reported the risk of CV outcomes for subgroups of older adults (≥ 65 years) with CV disease. The primary outcome was a composite of hospitalization for heart failure (HHF), urgent heart failure (HF) visits, and cardiovascular death (CVD). Secondary outcomes included all-cause mortality, CVD, and HHF individually. Subgroup analyses were conducted in patients with HF, T2DM, age strata (65-74 vs. ≥ 75), SGLT2 inhibitor agent, and adverse events.

Results: Analyzing nine studies, SGLT2 inhibitors were associated with reducing the risk of composite outcome (HR: 0.75, 95% CI: 0.67-0.83, I2 = 51%), all-cause mortality (HR: 0.80, 95% CI: 0.66-0.97, I2 = 68%), CVD (HR: 0.78, 95% CI: 0.65-0.94, I2 = 61%), and HHF (HR: 0.73, 95% CI: 0.65-0.83, I2 = 0%). Benefits were consistent in subgroups of HF only, T2DM only, and those aged ≥ 75 years. No significant differences were observed by SGLT2 inhibitor type (p = 0.090). SGLT2 inhibitors increased the risk of genital infections (RR: 3.18, 95% CI: 2.35-4.30, I2 = 0%) but decreased that of other serious adverse events (RR: 0.92, 95% CI: 0.86-0.97, I2 = 64%).

Conclusions: In adults aged ≥ 65 years with CV disease, SGLT2 inhibitors significantly reduce the composite risk of HHF, urgent HF visits, and CVD and secondary outcomes of all-cause mortality, CVD, and HHF, supporting their use in this population with careful monitoring of age-related risks.

Keywords: SGLT2 inhibitors; cardiovascular disease; meta‐analysis; older adults.

PubMed Disclaimer

References

    1. M. S. Usman, T. J. Siddiqi, S. D. Anker, et al., “Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations,” Journal of the American College of Cardiology 81, no. 25 (2023): 2377–2387, https://doi.org/10.1016/j.jacc.2023.04.034.
    1. T. A. Zelniker and E. Braunwald, “Mechanisms of Cardiorenal Effects of Sodium‐Glucose Cotransporter 2 Inhibitors: JACC State‐Of‐The‐Art Review,” Journal of the American College of Cardiology 75, no. 4 (2020): 422–434, https://doi.org/10.1016/j.jacc.2019.11.031.
    1. P. A. Heidenreich, B. Bozkurt, D. Aguilar, et al., “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 145, no. 18 (2022): e895–e1032, https://doi.org/10.1161/CIR.0000000000001063.
    1. T. A. McDonagh, M. Metra, M. Adamo, et al., “Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure [published correction appears in Eur Heart J 2024 Jan 1;45(1):53.],” European Heart Journal 44, no. 37 (2023): 3627–3639, https://doi.org/10.1093/eurheartj/ehad195.
    1. M. R. Cowie and M. Fisher, “SGLT2 Inhibitors: Mechanisms of Cardiovascular Benefit Beyond Glycaemic Control,” Nature Reviews. Cardiology 17, no. 12 (2020): 761–772, https://doi.org/10.1038/s41569‐020‐0406‐8.

LinkOut - more resources